// App-Quantinova.ai

P19.01 : RATIONALE-303 Phase 3 Tislelizumab vs Docetaxel in Previously Treated Advanced NSCLC: China Subgroup Analysis

Researchers

Presenter

  • Y. Fan

Principal Investigators

  • D. Huang

  • Z. Ma

  • X. Yu

  • Y. Cheng

  • Y. Ma

  • Y. Wang

  • Z. Pan

  • C. Yu

  • C. Zhou

Medical Centers

  • Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou/CN

  • Jilin Cancer Hospital, Jilin, China

  • Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou/CN

  • Department of Thoracic Medical Oncology, Lung Cancer Diagnosis and Treatment Center, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin/CN

  • Department of Respiratory Medicine, Affiliated Cancer Hospital of Zhengzhou University/henan Cancer Hospital, Zhengzhou/CN

  • Beigene (Beijing) Co., Ltd., Shanghai/CN

  • Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai/CN

Locations

  • China

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non Small Cell Lung cancer

Biomarkers

  • Programmed death-ligand 1

  • Cyclin Dependent Kinase Inhibitor 2A

Drug/Treatment

  • Tislelizumab

  • Docetaxel

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • NCT03358875

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved